Pilot Study for PET/MR Imaging of Covid-19

Pilot Study for Simultaneous PET-MR Imaging of Covid-19 Associated Neurological Complications Using a Brain Dedicated PET Insert

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04954248

Enrollment

Registered

2021-07-08

Start date

2022-07-01

Completion date

2023-09-20

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Diseases, Covid19

Brief summary

The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.

Detailed description

This study is a non-randomized non-treatment study. The intention of this work is an assessment of the PET insert technology, and not, for example, to perform a treatment assessment or drug assessment. This work will actively recruit 10 individuals (5 Covid-19 negative and 5 Covid-19 previously positive in the last 180 days) to perform imaging of the brain with an FDA-approved radiotracer.

Interventions

DIAGNOSTIC_TESTInjected radiotracer with PET Insert

1. Informed consent will be obtained before beginning any study procedures. 2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DEVICE_FEASIBILITY

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Whole body radiation dose in the last year of less than 5000 mrem determined via subject verbal history reporting 2. Must be at least 21 years of age 3. Deemed healthy to endure duration of imaging study as confirmed via study PI 4. Proof of COVID-19 viral or antibody testing within the timeframe of \>20 days but \<=180 days prior to scan.

Exclusion criteria

1. History of non-MRI compatible surgeries, implants, or activities 2. Pregnant or nursing 3. History of allergic reactions to PET radiotracers (via patient verbal report and /or medical record review.

Design outcomes

Primary

Measure	Time frame	Description
Image quality of PET/MR	Up to 24 months	The key specific measurement is that resulting PET/MR images are of high quality, with comparable or better resolution and noise than that seen in other published articles.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCraig Levin, M. Phil., PhD.

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026